Physician profile
Ryan S Raddin
NPI 1659588911
$2,331.18
in general payments reported to CMS, 2019-2025
20 companies · $30.65 in 2025
The $30.65 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $1,872 · 2021: $69.83 · 2022: $114 · 2023: $36.30 · 2024: $17.29 · 2025: $30.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $53.59 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $53.59 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,754.37 | 2020 | |
| Genentech USA, INC. | $111.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $70.91 | 2019-2022 | |
| Puma Biotechnology, INC. | $45.95 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.10 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $35.08 | 2019-2020 | |
| Medtronic, INC. | $34.30 | 2022-2024 | Osteocool Rf Ablation System |
| Pfizer INC. | $30.65 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $29.58 | 2020-2023 | Opdivo |
| Seagen INC. | $26.22 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.86 | 2023 | Tazverik |
| Sanofi-Aventis U.S. LLC | $17.72 | 2020 | |
| Glaxosmithkline, LLC. | $17.44 | 2021 | |
| Foundation Medicine, INC. | $16.73 | 2020 | |
| Merck Sharp & Dohme LLC | $16.66 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurobindo Pharma USA, INC. | $16.01 | 2019 | |
| Verastem, INC. | $13.84 | 2020 | |
| Emd Serono, INC. | $13.74 | 2019 | |
| Gilead Sciences, INC. | $12.97 | 2021 | |
| Amgen INC. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Raddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.